Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company R&D

Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano

Fineline Cube Nov 24, 2022

Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...

Company Drug

Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial

Fineline Cube Nov 24, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval...

Company Deals

Saint Medical Raises Pre-Series B Funding for Structural Heart Disease Solutions

Fineline Cube Nov 24, 2022

Saint Medical Technology, a Nanjing-based medical device maker specializing in valvular disease solutions, has reportedly...

Company Drug

Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study

Fineline Cube Nov 24, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...

Company Drug

Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer

Fineline Cube Nov 24, 2022

China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...

Company Drug

Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug

Fineline Cube Nov 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...

Company Drug

Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne

Fineline Cube Nov 24, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...

Company Drug Legal / IP

FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft

Fineline Cube Nov 23, 2022

US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng...

Company Deals

JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston

Fineline Cube Nov 23, 2022

Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...

Company Deals

Jianke.com Files for Hong Kong IPO with Focus on Chronic Disease Management

Fineline Cube Nov 23, 2022

China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering...

Company Drug

China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study

Fineline Cube Nov 23, 2022

RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...

Policy / Regulatory

Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs

Fineline Cube Nov 23, 2022

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will...

Company Drug

BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting

Fineline Cube Nov 23, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present...

Company Deals

Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening

Fineline Cube Nov 23, 2022

Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...

Company Deals Medical Device

Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development

Fineline Cube Nov 23, 2022

Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised...

Company Drug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Fineline Cube Nov 23, 2022

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA

Fineline Cube Nov 23, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...

Company Drug

InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore

Fineline Cube Nov 23, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...

Company Deals

Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma

Fineline Cube Nov 23, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...

Company Deals

UB Biotechnology Secures Series A Funding for Flow Cytometry Platform

Fineline Cube Nov 22, 2022

China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens...

Posts pagination

1 … 636 637 638 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.